Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Overview

authors

Suzuki, Tatsuya

Wakayama, Kentaro

Kurth, Renate I

Fujita, Hidenori

Mattar, Marissa S

Funabashi, Kaoru

Ohkubo, Shuichi

Terada, Ryuichiro

Giuliano, Claudio

Lu, Yue Christine

Bonifacio, Annalisa

Kunte, Siddharth

Davare, Monika A

Cheng, Emily
de Stanchina, Elisa
Lovati, Emanuela
Iwasawa, Yoshikazu
Ladanyi, Marc
Somwar, Romel

publication date

October 9, 2023

published in

Nature cancer Journal

Identity

Digital Object Identifier (DOI)

10.1038/s43018-023-00663-3

PubMed ID

37814012